The Program in Gene Regulation and Functional Genomics (GRFGP) is derived from the former Molecular Oncology Program (MOP) which was renamed to reflect a more sharpened focus. The reorganization reflects the profound developments that have occurred in the molecular genetics of cancer, as well as in the broader field of genomics, since the last competitive renewal of this grant. Under the joint leadership of Dr. Jeffrey Sklar and Dr. Sherman Weissman (former co-Leader of MOP), the GRFGP is designed to promote (1) research into the mechanisms and effects of gene expression relevant to the neoplastic phenotype, and (2) the investigation of cancer-associated broad-based structural and functional features of the human genome. These two aspects of the GRFGP cover the study of individual genes that contribute to the development and progression of cancer as well as the analysis of genome-wide gene expression, chromatin structure, and regulatory factors that characterize or control the neoplastic state. Furthermore, the goals of the research encompassed by this program include the development of methods to better elucidate and analyze the changes in genes, gene expression, and DNA related to cancer. Finally, this program is interested in both the biologic processes underlying cancer and the application of information about those processes to the improved prevention, diagnosis, and treatment of cancer. By focusing predominantly on the molecular analysis of sporadic cancers, the GRFGP complements the activities of the Cancer Genetics Program, which is charged with the identification and analysis of genes responsible for hereditary predisposition to cancer. The two Programs engage in significant collaborations, particularly in the area of technology development. The goals of the GRFGP are accomplished through joint sponsorship of the Molecular Virology and Oncology group meetings, major participation in the Stem Cell weekly group meetings, organization of the weekly Genetics Seminar series, institution of Pilot Grant program to stimulate programmatically-oriented research in cancer, as well as by facilitating collaboration between members within the program and other Cancer Center programs. The GRFGP consists of 20 independent but interactive members belonging to eight departments of the Medical School or University. Total peer-reviewed funding support of this group is approximately $4.7 million direct costs annually ($7.5 million total costs), of which just under $1 million direct costs ($1.4 total costs) come from NCI. Total direct funding is $4,79 million ($7.65 million total costs). During the previous grant period, members of this program published 208 cancer-related papers, of which 5.3% were intraprogrammatic and 15.9% inter-programmatic

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-33
Application #
8312354
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
33
Fiscal Year
2011
Total Cost
$29,701
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications